Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) FCF Margin (2016 - 2025)

Haemonetics has reported FCF Margin over the past 17 years, most recently at 25.73% for Q4 2025.

  • For Q4 2025, FCF Margin rose 1562.0% year-over-year to 25.73%; the TTM value through Dec 2025 reached 23.37%, up 1617.0%, while the annual FY2025 figure was 10.47%, 50.0% down from the prior year.
  • FCF Margin for Q4 2025 was 25.73% at Haemonetics, down from 32.48% in the prior quarter.
  • Over five years, FCF Margin peaked at 32.48% in Q3 2025 and troughed at 9.84% in Q2 2024.
  • A 5-year average of 10.01% and a median of 10.75% in 2024 define the central range for FCF Margin.
  • Biggest five-year swings in FCF Margin: tumbled -2010bps in 2023 and later surged 2114bps in 2024.
  • Year by year, FCF Margin stood at 9.44% in 2021, then surged by 65bps to 15.58% in 2022, then crashed by -129bps to 4.52% in 2023, then soared by 324bps to 10.1% in 2024, then skyrocketed by 155bps to 25.73% in 2025.
  • Business Quant data shows FCF Margin for HAE at 25.73% in Q4 2025, 32.48% in Q3 2025, and 4.24% in Q2 2025.